StemCardia

StemCardia is a regenerative medicine company focused on developing cell-based therapies to treat heart failure and other cardiovascular diseases. The company leverages technology developed by Dr. Charles Murry to produce high-purity cardiomyocytes from induced pluripotent stem cells (iPSCs). These cells are intended to be transplanted into the hearts of patients who have suffered muscle loss due to myocardial infarction, with the goal of remuscularizing the heart and restoring function. By replacing lost cardiac muscle rather than merely slowing disease progression, StemCardia aims to provide a definitive treatment for heart failure. The company is currently progressing its lead candidates through pre-clinical studies to support future clinical applications.